435 related articles for article (PubMed ID: 33235684)
1. Utilization of myositis antibody-specific panel for diagnosis, treatment, and evaluation of disease progression.
Stark A; Hauptman H; Nguyen B; Mathew M; Aversano A; Mueller J
J Community Hosp Intern Med Perspect; 2020 Sep; 10(5):462-465. PubMed ID: 33235684
[TBL] [Abstract][Full Text] [Related]
2. Clinical and pathological features of immune-mediated necrotising myopathies in a single-centre muscle biopsy cohort.
Yang H; Tian X; Zhang L; Li W; Liu Q; Jiang W; Peng Q; Wang G; Lu X
BMC Musculoskelet Disord; 2022 May; 23(1):425. PubMed ID: 35524238
[TBL] [Abstract][Full Text] [Related]
3. Immune-mediated necrotizing myopathy (IMNM): A myopathological challenge.
Merlonghi G; Antonini G; Garibaldi M
Autoimmun Rev; 2022 Feb; 21(2):102993. PubMed ID: 34798316
[TBL] [Abstract][Full Text] [Related]
4. Classification of idiopathic inflammatory myopathies: pathology perspectives.
Tanboon J; Nishino I
Curr Opin Neurol; 2019 Oct; 32(5):704-714. PubMed ID: 31369423
[TBL] [Abstract][Full Text] [Related]
5. Inflammatory myopathies: an update for neurologists.
Silva AMS; Campos ED; Zanoteli E
Arq Neuropsiquiatr; 2022 May; 80(5 Suppl 1):238-248. PubMed ID: 35976321
[TBL] [Abstract][Full Text] [Related]
6. [Classification of idiopathic inflammatory myopathies based on clinical manifestations and myositis-specific antibodies].
Zheng S; Chen S; Wu L; Zhao D; Chen F; Zhu J; Li J
Nan Fang Yi Ke Da Xue Xue Bao; 2020 Jul; 40(7):1029-1035. PubMed ID: 32895158
[TBL] [Abstract][Full Text] [Related]
7. Polymyositis: is there anything left? A retrospective diagnostic review from a tertiary myositis centre.
Loarce-Martos J; Lilleker JB; Parker M; McHugh N; Chinoy H
Rheumatology (Oxford); 2021 Jul; 60(7):3398-3403. PubMed ID: 33367878
[TBL] [Abstract][Full Text] [Related]
8. Radiographic patterns of muscle involvement in the idiopathic inflammatory myopathies.
Day JA; Bajic N; Gentili S; Patel S; Limaye V
Muscle Nerve; 2019 Nov; 60(5):549-557. PubMed ID: 31397909
[TBL] [Abstract][Full Text] [Related]
9. [Myositis: From classification to diagnosis].
Fer F; Allenbach Y; Benveniste O
Rev Med Interne; 2021 Jun; 42(6):392-400. PubMed ID: 33248855
[TBL] [Abstract][Full Text] [Related]
10. Integrated analysis of plasma and urine reveals unique metabolomic profiles in idiopathic inflammatory myopathies subtypes.
Liu D; Zhao L; Jiang Y; Li L; Guo M; Mu Y; Zhu H
J Cachexia Sarcopenia Muscle; 2022 Oct; 13(5):2456-2472. PubMed ID: 35860906
[TBL] [Abstract][Full Text] [Related]
11. Immune-Mediated Necrotizing Myopathy: Update on Diagnosis and Management.
Basharat P; Christopher-Stine L
Curr Rheumatol Rep; 2015 Dec; 17(12):72. PubMed ID: 26515574
[TBL] [Abstract][Full Text] [Related]
12. Heterogeneous clinical spectrum of anti-SRP myositis and importance of the methods of detection of anti-SRP autoantibodies: a multicentric study.
Picard C; Vincent T; Lega JC; Hue S; Fortenfant F; Lakomy D; Humbel RL; Goetz J; Molinari N; Bardin N; Bertin D; Johanet C; Chretien P; Dubucquoi S; Streichenberger N; Desplat-Jégo S; Bossuyt X; Sibilia J; Abreu I; Chevailler A; Fabien N
Immunol Res; 2016 Jun; 64(3):677-86. PubMed ID: 26744256
[TBL] [Abstract][Full Text] [Related]
13. Potential Pathogenic Role of Anti-Signal Recognition Protein and Anti-3-hydroxy-3-methylglutaryl-CoA Reductase Antibodies in Immune-Mediated Necrotizing Myopathies.
Ladislau L; Arouche-Delaperche L; Allenbach Y; Benveniste O
Curr Rheumatol Rep; 2018 Aug; 20(9):56. PubMed ID: 30074107
[TBL] [Abstract][Full Text] [Related]
14. Autoantibodies: Pathogenic or epiphenomenon.
Galindo-Feria AS; Wang G; Lundberg IE
Best Pract Res Clin Rheumatol; 2022 Jun; 36(2):101767. PubMed ID: 35810122
[TBL] [Abstract][Full Text] [Related]
15. Inflammatory muscle disease - An update.
Baig S; Paik JJ
Best Pract Res Clin Rheumatol; 2020 Feb; 34(1):101484. PubMed ID: 32046904
[TBL] [Abstract][Full Text] [Related]
16. Paraneoplastic myopathies.
Mammen AL
Handb Clin Neurol; 2024; 200():327-332. PubMed ID: 38494286
[TBL] [Abstract][Full Text] [Related]
17. Correlation of clinicoserologic and pathologic classifications of inflammatory myopathies: study of 178 cases and guidelines for diagnosis.
Fernandez C; Bardin N; De Paula AM; Salort-Campana E; Benyamine A; Franques J; Schleinitz N; Weiller PJ; Pouget J; Pellissier JF; Figarella-Branger D
Medicine (Baltimore); 2013 Jan; 92(1):15-24. PubMed ID: 23269233
[TBL] [Abstract][Full Text] [Related]
18. Development of a New Classification System for Idiopathic Inflammatory Myopathies Based on Clinical Manifestations and Myositis-Specific Autoantibodies.
Mariampillai K; Granger B; Amelin D; Guiguet M; Hachulla E; Maurier F; Meyer A; Tohmé A; Charuel JL; Musset L; Allenbach Y; Benveniste O
JAMA Neurol; 2018 Dec; 75(12):1528-1537. PubMed ID: 30208379
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Muscle Biopsy Features with Myositis Autoantibodies in Inflammatory Myopathies: A Pilot Experience.
Gudipati A; Rifat S; Uppin M; Jabeen A; Mathukumalli NL; Yareeda S; Kayidhi S; Pyal A; Dhamne M; Reddy YM
Ann Indian Acad Neurol; 2023; 26(4):408-418. PubMed ID: 37970294
[TBL] [Abstract][Full Text] [Related]
20. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups.
Love LA; Leff RL; Fraser DD; Targoff IN; Dalakas M; Plotz PH; Miller FW
Medicine (Baltimore); 1991 Nov; 70(6):360-74. PubMed ID: 1659647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
